These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. The role of fetal nuchal translucency and ductus venosus Doppler at 11-14 weeks of gestation in the detection of major congenital heart defects. Favre R; Cherif Y; Kohler M; Kohler A; Hunsinger MC; Bouffet N; Tanghe M; Cancellier M; Nisand I Ultrasound Obstet Gynecol; 2003 Mar; 21(3):239-43. PubMed ID: 12666217 [TBL] [Abstract][Full Text] [Related]
43. Fetal heart rate and nuchal translucency in detecting chromosomal abnormalities other than Down syndrome. Martinez JM; Echevarría M; Borrell A; Puerto B; Ojuel J; Fortuny A Obstet Gynecol; 1998 Jul; 92(1):68-71. PubMed ID: 9649096 [TBL] [Abstract][Full Text] [Related]
44. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome. Kadir RA; Economides DL Ultrasound Obstet Gynecol; 1997 Apr; 9(4):244-7. PubMed ID: 9168574 [TBL] [Abstract][Full Text] [Related]
45. First-trimester screening for chromosomal abnormalities by fetal nuchal translucency in a Brazilian population. Brizot ML; Carvalho MH; Liao AW; Reis NS; Armbruster-Moraes E; Zugaib M Ultrasound Obstet Gynecol; 2001 Dec; 18(6):652-5. PubMed ID: 11844209 [TBL] [Abstract][Full Text] [Related]
46. First-trimester nuchal translucency and cardiac septal defects in fetuses with trisomy 21. Hyett JA; Moscoso G; Nicolaides KH Am J Obstet Gynecol; 1995 May; 172(5):1411-3. PubMed ID: 7755046 [TBL] [Abstract][Full Text] [Related]
47. Four years experience of first-trimester nuchal translucency screening for fetal aneuploidies with increasing regional availability. Wayda K; Keresztúri A; Orvos H; Horváth E; PAl A; Kovács L; Szabó J Acta Obstet Gynecol Scand; 2001 Dec; 80(12):1104-9. PubMed ID: 11846706 [TBL] [Abstract][Full Text] [Related]
48. Fetal heart rate in trisomy 21 and other chromosomal abnormalities at 10-14 weeks of gestation. Hyett JA; Noble PL; Snijders RJ; Montenegro N; Nicolaides KH Ultrasound Obstet Gynecol; 1996 Apr; 7(4):239-44. PubMed ID: 8726874 [TBL] [Abstract][Full Text] [Related]
49. First-trimester screening for trisomies 18 and 13, triploidy and Turner syndrome by detailed early anomaly scan. Wagner P; Sonek J; Hoopmann M; Abele H; Kagan KO Ultrasound Obstet Gynecol; 2016 Oct; 48(4):446-451. PubMed ID: 26611869 [TBL] [Abstract][Full Text] [Related]
50. Ultrasonographic markers for chromosomal abnormalities in women with negative nuchal translucency and second trimester maternal serum biochemistry. Verdin SM; Whitlow BJ; Lazanakis M; Kadir RA; Chatzipapas I; Economides DL Ultrasound Obstet Gynecol; 2000 Oct; 16(5):402-6. PubMed ID: 11169322 [TBL] [Abstract][Full Text] [Related]
51. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks. Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509 [TBL] [Abstract][Full Text] [Related]
53. Comparison between two methods of standardization for gestational age differences in fetal nuchal translucency measurement in first-trimester screening for trisomy 21. Biagiotti R; Periti E; Brizzi L; Vanzi E; Cariati E Ultrasound Obstet Gynecol; 1997 Apr; 9(4):248-52. PubMed ID: 9168573 [TBL] [Abstract][Full Text] [Related]
54. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany. Soergel P; Pruggmayer M; Schwerdtfeger R; Muhlhaus K; Scharf A Fetal Diagn Ther; 2006; 21(3):264-8. PubMed ID: 16601335 [TBL] [Abstract][Full Text] [Related]
55. Screening for chromosomal abnormalities in an unselected population by fetal nuchal translucency. Hafner E; Schuchter K; Philipp K Ultrasound Obstet Gynecol; 1995 Nov; 6(5):330-3. PubMed ID: 8590203 [TBL] [Abstract][Full Text] [Related]
56. Relationship between nuchal translucency at 11-14 weeks and nuchal fold at 20-24 weeks of gestation. Salomon LJ; Bernard JP; Taupin P; Benard C; Ville Y Ultrasound Obstet Gynecol; 2001 Dec; 18(6):636-7. PubMed ID: 11844204 [TBL] [Abstract][Full Text] [Related]
57. Sonographic screening for fetal aneuploidy: first trimester. Souter VL; Nyberg DA J Ultrasound Med; 2001 Jul; 20(7):775-90. PubMed ID: 11444737 [TBL] [Abstract][Full Text] [Related]
58. Changes in nuchal translucency thickness in normal and abnormal karyotype fetuses. Zoppi MA; Ibba RM; Floris M; Manca F; Axiana C; Monni G BJOG; 2003 Jun; 110(6):584-8. PubMed ID: 12798476 [TBL] [Abstract][Full Text] [Related]
59. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening. Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371 [TBL] [Abstract][Full Text] [Related]
60. Predictive value of increased nuchal translucency as a screening test for the detection of fetal chromosomal abnormalities. Alexioy E; Alexioy E; Trakakis E; Kassanos D; Farmakidis G; Kondylios A; Laggas D; Salamalekis E; Florentin L; Kanavakis E; Basios G; Trompoukis P; Georgiadoy L; Panagiotopoulos T J Matern Fetal Neonatal Med; 2009 Oct; 22(10):857-62. PubMed ID: 19521928 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]